Work

Abstract PS1-08-27: Randomized open-label multicenter phase 2 trial comparing first-line olaparib versus CDK4/6 inhibitor plus endocrine therapy in patients with gBRCAmut-associated HR+/HER2- advanced breast cancer [BR21-08, OPERA trial]

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps1-08-27

Authors: J. Kim, J. Kim, S.-H. Shin, K. Lee, J. Lee, J. Sohn, H. Kim, K. Lee, H. Won, J. Jung, K. Park

Institutions: Yonsei University, Korea University, Korea University Medical Center, Yonsei University Health System, Kosin University Gospel Hospital, Ewha Womans University, National Cancer Center, Ewha Womans University Seoul Hospital, Catholic University of Korea, Hallym University Dongtan Sacred Heart Hospital

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129651494

Cites:

Cited by:

Related to: